ѻý

Snort to Treat Social Anxiety; Zuranolone Flops in Depression Trial

<ѻý class="mpt-content-deck">— News and commentary from the psychiatry world
MedpageToday
Illustration of a brain shaped maze.

PH94B, a neuroactive , was just granted fast track designation by the FDA, VistaGen Therapeutics announced.

SSRIs had than SNRIs in children and adolescents. (ScienceDaily)

Having a "," such as a personal item or song, can help combat and slow down episodes of fear and anxiety. (PNAS)

The for Sage's fast-acting depression drug SAGE-217, a.k.a. zuranolone, missed its primary endpoint measured at day 15, the company said.

Not so surprising: new data suggests around a third of patients with . "Some oncologists may have a mindset that 'of course, you're depressed, you have lung cancer.' This may show an under-appreciation of the breadth of depressive symptoms and other difficulties which accompany it," said lead author Barbara Andersen, PhD, of Ohio State University. (Lung Cancer)

Young adults with ADHD were at higher risk for becoming . (Neuropsychopharmacology)

-- otherwise known as PATH -- may help patients with depression and mild cognitive impairment. (New York Times)

Although older adults nowadays may not be necessarily , a new study suggested lonely adults are more numerous than ever. (ScienceDaily)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.